养老院独立药师处方服务有效性与成本效果整群随机对照试验方案(CHIPPS研究)
CHIPPS研究为一项含3个月内部预试验的整群随机对照试验方案,旨在评估养老院中由药师独立处方者(PIP)提供处方服务相较于常规全科医生主导照护的有效性与成本效果。主要结局为6个月时居民跌倒,目标样本为44个三元组共880名居民,目前已开始招募,预计2020年初完成。
要点
- 养老院用药管理需专人统筹,药师独立处方服务在此场景可行。
- 主要结局为6个月跌倒,目标880名居民,可检测跌倒率相对下降21%。
- 干预由PIP与全科医生协作,涵盖用药审核、药品 care 计划及人员培训。
核心结论
- 该方案拟通过整群随机对照试验明确养老院药师独立处方服务的有效性与成本效果,结果将影响养老院居民用药管理及该服务的后续推广。
研究设计与样本
- 整群随机对照试验方案,含3个月内部预试验以确认招募可行且无安全性问题。
- 随机单位为三元组,由一名驻全科诊所的药师独立处方者及足够注册居民(平均可招募20名参与者)的一个或多个养老院组成。
- 目标样本量为44个三元组共880名居民(每臂440名)。
主要发现
- 原文未报告试验结果,仅报告方案设计与样本量估算。
关键数值与推荐
- 主要结局为6个月时居民跌倒。
- 样本量880名居民可检测跌倒率从每人1.5降至1.178(相对下降21%),把握度80%,ICC≤0.05。
- 干预持续6个月;次要结局包括健康相关生活质量、3个月跌倒、用药负担、用药适当性、死亡与住院。
- 将开展完整卫生经济学分析。
临床怎么用
- 干预组PIP与全科医生协作,承担居民处方与用药管理(含用药审核和药学 care 计划)。
- PIP支持养老院、全科诊所与供药药房的系统化订购与给药,并培训相关人员。
局限性
- 原文为研究方案,尚未报告试验结果,有效性与成本效果结论待试验完成后得出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prescribing, monitoring and administration of medicines in care homes could be improved. Research has identified the need for one person to assume overall responsibility for the management of medicines within each care home. and shown that a pharmacist independent prescriber service is feasible in this context. AIMS AND OBJECTIVES: To conduct a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of a pharmacist-independent prescribing service in care homes compared to usual general practitioner (GP)-led care. OBJECTIVES: To perform a definitive randomised controlled trial (RCT) with an internal pilot to determine the intervention's effectiveness and cost-effectiveness and enable modelling beyond the end of the trial. METHODS: This protocol is for a cluster RCT with a 3-month internal pilot to confirm that recruitment is achievable, and there are no safety concerns. The unit of randomisation is a triad comprising a pharmacist-independent prescriber (PIP) based in a GP practice with sufficient registered patients resident in one or more care homes to allow recruitment of an average of 20 participants. In the intervention group, the PIP will, in collaboration with the GP: assume responsibility for prescribing and managing residents' medicines including medication review and pharmaceutical care planning; support systematic ordering and administration in the care home, GP practice and supplying pharmacy; train care home and GP practice staff; communicate with GP practice, care home, supplying community pharmacy and study team. The intervention will last 6 months. The primary outcome will be resident falls at 6 months. Secondary outcomes include resident health-related quality of life, falls at 3 months, medication burden, medication appropriateness, mortality and hospitalisations. A full health economic analysis will be undertaken. The target sample size is 880 residents (440) in each arm) from 44 triads. This number is sufficient to detect a decrease in fall rate from 1.5 per individual to 1.178 (relative reduction of 21%) with 80% power and an ICC of 0.05 or less. DISCUSSION: Recruitment is on-going and the trial should complete in early 2020. The trial results will have implications for the future management of residents in care homes and the ongoing implementation of independent pharmacist prescribing. TRIAL REGISTRATION: ISRCTN, ID: 17847169. Registered on 15 December 2017.
引用
- Bond CM, Holland R, Alldred DP, et al. Protocol for a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care homes: the CHIPPS study. Trials. 2020. PMID: 31964398. doi:10.1186/s13063-019-3827-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。